Journey Medical (DERM) Competitors

$5.96 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$6.02 +0.07 (+1.09%)

As of 05/22/2026 05:31 PM Eastern

DERM vs. FBIO, BIOA, CYRX, DSGN, and RLMD

Should you buy Journey Medical stock or one of its competitors? MarketBeat compares Journey Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Journey Medical include Fortress Biotech (FBIO), BioAge Labs (BIOA), CryoPort (CYRX), Design Therapeutics (DSGN), and Relmada Therapeutics (RLMD).

How does Journey Medical compare to Fortress Biotech?

Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Journey Medical had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 7 mentions for Journey Medical and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Journey Medical's score of -0.28 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Journey Medical presently has a consensus target price of $13.00, indicating a potential upside of 118.12%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 520.44%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 193.12% compared to Journey Medical's net margin of -14.82%. Fortress Biotech's return on equity of 109.66% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Fortress Biotech	193.12%	109.66%	45.56%

Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.63	-$11.43M	-$0.37	N/A
Fortress Biotech	$63.26M	1.44	$6.82M	$3.17	0.86

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Journey Medical on 12 of the 14 factors compared between the two stocks.

How does Journey Medical compare to BioAge Labs?

Journey Medical (NASDAQ:DERM) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Journey Medical has higher revenue and earnings than BioAge Labs. Journey Medical is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.63	-$11.43M	-$0.37	N/A
BioAge Labs	$8.99M	82.13	-$80.61M	-$2.40	N/A

Journey Medical has a net margin of -14.82% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
BioAge Labs	-871.75%	-29.40%	-27.26%

Journey Medical currently has a consensus target price of $13.00, indicating a potential upside of 118.12%. BioAge Labs has a consensus target price of $45.00, indicating a potential upside of 170.92%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

7.3% of Journey Medical shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

In the previous week, Journey Medical had 4 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Journey Medical and 3 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.22 beat Journey Medical's score of -0.28 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Journey Medical and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does Journey Medical compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Journey Medical (NASDAQ:DERM) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, Journey Medical had 3 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Journey Medical and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.12 beat Journey Medical's score of -0.28 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 10.0% of CryoPort shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.00	$78.30M	$1.35	10.37
Journey Medical	$61.86M	2.63	-$11.43M	-$0.37	N/A

CryoPort presently has a consensus target price of $14.69, suggesting a potential upside of 4.91%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 118.12%. Given Journey Medical's higher probable upside, analysts clearly believe Journey Medical is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

CryoPort has a net margin of 41.57% compared to Journey Medical's net margin of -14.82%. CryoPort's return on equity of -7.92% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Journey Medical	-14.82%	-35.57%	-10.88%

CryoPort has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

CryoPort beats Journey Medical on 13 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Design Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Design Therapeutics' return on equity of -33.07% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Journey Medical	-14.82%	-35.57%	-10.88%

Journey Medical has higher revenue and earnings than Design Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Journey Medical	$61.86M	2.63	-$11.43M	-$0.37	N/A

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 23.5% of Design Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 50.41%. Journey Medical has a consensus price target of $13.00, suggesting a potential upside of 118.12%. Given Journey Medical's higher possible upside, analysts clearly believe Journey Medical is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Journey Medical had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Journey Medical and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.44 beat Journey Medical's score of -0.28 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Design Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Summary

Design Therapeutics beats Journey Medical on 10 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Relmada Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 70.45%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 118.12%. Given Journey Medical's higher probable upside, analysts plainly believe Journey Medical is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Relmada Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Journey Medical	-14.82%	-35.57%	-10.88%

Journey Medical has higher revenue and earnings than Relmada Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Journey Medical	$61.86M	2.63	-$11.43M	-$0.37	N/A

In the previous week, Journey Medical had 7 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Journey Medical and 0 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat Journey Medical's score of -0.28 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
Journey Medical	Neutral

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 15.0% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Journey Medical beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$162.89M	$3.04B	$6.45B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-16.11	17.79	21.22	25.65
Price / Sales	2.63	336.21	553.92	86.28
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	5.27	5.86	10.37	7.14
Net Income	-$11.43M	$74.99M	$3.57B	$335.98M
7 Day Performance	-4.64%	2.55%	6.01%	3.56%
1 Month Performance	15.73%	-3.05%	3.52%	2.54%
1 Year Performance	-14.86%	34.38%	34.13%	35.05%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	2.3814 of 5 stars	$5.96 flat	$13.00 +118.1%	-14.9%	$162.89M	$61.86M	N/A	90	Gap Down
FBIO Fortress Biotech	3.4534 of 5 stars	$2.53 +2.0%	$17.00 +571.9%	+53.9%	$82.38M	$63.26M	0.80	170	Analyst Upgrade
BIOA BioAge Labs	2.8353 of 5 stars	$16.37 +6.7%	$45.00 +174.9%	N/A	$681.91M	$8.99M	N/A	N/A
CYRX CryoPort	3.1574 of 5 stars	$13.03 -2.1%	$14.44 +10.8%	+131.8%	$670.85M	$176.18M	9.65	1,186
DSGN Design Therapeutics	3.3802 of 5 stars	$10.49 -2.0%	$16.50 +57.3%	+187.9%	$668.29M	N/A	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, BIOA, CYRX, DSGN, and RLMD

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to BioAge Labs?

Summary

How does Journey Medical compare to CryoPort?

Summary

How does Journey Medical compare to Design Therapeutics?

Summary

How does Journey Medical compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, BIOA, CYRX, DSGN, and RLMD

How does Journey Medical compare to Fortress Biotech?

Does the media prefer DERM or FBIO?

Do analysts rate DERM or FBIO?

Is DERM or FBIO more profitable?

Which has more volatility & risk, DERM or FBIO?

Which has stronger earnings and valuation, DERM or FBIO?

Do institutionals & insiders believe in DERM or FBIO?

Summary

How does Journey Medical compare to BioAge Labs?

Which has better valuation and earnings, DERM or BIOA?

Is DERM or BIOA more profitable?

Do analysts rate DERM or BIOA?

Do insiders & institutionals believe in DERM or BIOA?

Which has more risk and volatility, DERM or BIOA?

Does the media prefer DERM or BIOA?

Summary

How does Journey Medical compare to CryoPort?

Does the media refer more to CYRX or DERM?

Do insiders & institutionals believe in CYRX or DERM?

Which has better valuation & earnings, CYRX or DERM?

Do analysts recommend CYRX or DERM?

Is CYRX or DERM more profitable?

Which has more volatility & risk, CYRX or DERM?

Summary

How does Journey Medical compare to Design Therapeutics?

Is DSGN or DERM more profitable?

Which has higher earnings & valuation, DSGN or DERM?

Do institutionals and insiders hold more shares of DSGN or DERM?

Do analysts rate DSGN or DERM?

Does the media favor DSGN or DERM?

Which has more volatility & risk, DSGN or DERM?

Summary

How does Journey Medical compare to Relmada Therapeutics?

Which has more risk and volatility, RLMD or DERM?

Do analysts rate RLMD or DERM?

Is RLMD or DERM more profitable?

Which has preferable valuation & earnings, RLMD or DERM?

Does the media refer more to RLMD or DERM?

Do institutionals & insiders believe in RLMD or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools